← Leaderboards
Stephen Starko Francis
University Of California, San Francisco
$2,607,031
Attributed
$2,607,031
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $669.1K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,607,031 · 1
By mechanism
R01$2,607,031 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Jill Allison Hollenbach$14,012,161
- Steven John Mack$2,482,894
- Hideho Okada$20,052,698
- Eric Alejandro Sweet-Cordero$20,798,239
- Scarlett L Gomez$14,448,454
Others in their field
Other Rising Stars on “Genes”
- Mari Ostendorf · University Of Washington$51,931,230
- Suma Babu · Massachusetts General Hospital$28,791,731
- Sabrina Paganoni · Massachusetts General Hospital$28,791,731
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
Research focus
GenesAllelesAffectAdult GliomaAmino Acid SequenceAntibody ResponseAntigenic VariationAmino Acid MotifsAmino AcidsAreaBindingBk VirusCase ControlCellsClinical DataCo-InfectionCytomegalovirusDetectionAntigensEpidemiologic DataEpidemiology StudyEtiologyFoundationsGenetic
Grant awards (4)
Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and Immunogenomics$661,410
R01 · FY2025 · CA · contact PI
Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and Immunogenomics$630,449
R01 · FY2024 · CA · contact PI
Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and Immunogenomics$646,077
R01 · FY2023 · CA · contact PI
Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and Immunogenomics$669,095
R01 · FY2022 · CA · contact PI